Sobi™ Completes Acquisition of Synagis® US Rights From AstraZeneca and Exercises Authorisation to Issue Shares

Sobi™ Completes Acquisition of Synagis® US Rights From AstraZeneca and Exercises Authorisation to Issue Shares - BioSpace

January 29, 2019

Sobi™ Completes Acquisition of Synagis® US Rights From AstraZeneca and Exercises Authorisation to Issue Shares BioSpace

Published: Jan 24, 2019. STOCKHOLM, Jan. 24, 2018 /PRNewswire/ --Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) announced today that it has ...

RSV Treatment

Sobi™ Completes Acquisition of Synagis® US Rights From AstraZeneca and Exercises Authorisation to Issue Shares - BioSpace

Comments

Post a Comment

Popular posts from this blog

Analysis | The Keys to Speed in Race for Vaccine, and Its Perils - Washington Post

Prematurity Awareness Month: Educating the public about Respiratory Syncytial Virus is vital, claims leading consultant - ZAWYA

Oishei Children's Hospital Seeing Spike in RSV Cases - Spectrum News